Cytokinetics (CYTK) Financials

$32.66 +1.91 (+6.21%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for Cytokinetics

This table shows Cytokinetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-590	-526	-389	-215	-127	-122	-106	-128	16	-38
Consolidated Net Income / (Loss)	-590	-526	-389	-215	-127	-122	-106	-128	16	-38
Net Income / (Loss) Continuing Operations	-590	-526	-389	-215	-127	-122	-106	-128	16	-38
Total Pre-Tax Income	-641	-554	-400	-216	-133	-122	-106	-128	16	-38
Total Operating Income	-536	-496	-324	-186	-94	-99	-89	-113	19	-37
Total Gross Profit	18	7.53	95	70	56	27	32	13	106	29
Total Revenue	18	7.53	95	70	56	27	32	13	106	29
Operating Revenue	18	7.53	95	70	56	27	32	13	-	-
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	555	504	419	257	150	126	120	127	88	66
Selling, General & Admin Expense	215	174	178	97	53	40	31	36	28	20
Research & Development Expense	339	330	241	160	97	86	89	90	60	46
Total Other Income / (Expense), net	-105	-58	-76	-29	-39	-23	-17	-14	-2.23	-0.09
Interest Expense	87	58	51	29	39	27	22	17	2.70	0.27
Other Income / (Expense), net	-18	0.00	-25	0.00	0.00	4.54	4.35	2.60	0.46	0.17
Other Gains / (Losses), net	52	28	11	0.33	5.33	-	-	-	-	-
Basic Earnings per Share	($5.26)	($5.45)	($4.33)	($2.80)	($1.97)	($2.11)	($1.95)	($2.59)	$0.41	($0.97)
Weighted Average Basic Shares Outstanding	111.98M	96.52M	89.83M	76.89M	64.52M	57.58M	54.42M	49.40M	39.94M	38.81M
Diluted Earnings per Share	($5.26)	($5.45)	($4.33)	($2.80)	($1.97)	($2.11)	($1.95)	($2.59)	$0.39	($0.97)
Weighted Average Diluted Shares Outstanding	111.98M	96.52M	89.83M	76.89M	64.52M	57.58M	54.42M	49.40M	42.56M	38.81M
Weighted Average Basic & Diluted Shares Outstanding	118.41M	103.00M	95.16M	76.89M	64.52M	57.58M	54.42M	49.40M	41.73M	38.70M

This table shows Cytokinetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-161	-150	-161	-144	-136	-138	-129	-128	-131	-137	-142
Consolidated Net Income / (Loss)	-161	-150	-161	-143	-136	-137	-129	-129	-131	-137	-142
Net Income / (Loss) Continuing Operations	-161	-150	-161	-144	-136	-137	-129	-129	-131	-137	-142
Total Pre-Tax Income	-175	-176	-178	-144	-144	-158	-129	-129	-138	-147	-142
Total Operating Income	-156	-139	-141	-130	-126	-127	-122	-122	-124	-127	-108
Total Gross Profit	1.58	17	0.46	0.25	0.84	1.67	0.38	0.87	4.61	1.96	2.52
Total Revenue	1.58	17	0.46	0.25	0.84	1.67	0.38	0.87	4.61	1.96	2.52
Operating Revenue	1.58	17	0.46	0.25	0.84	1.67	0.38	0.87	4.61	1.96	2.52
Total Cost of Revenue	0.00	-	0.00	0.00	0.00	-	0.00	0.00	0.00	-	0.00
Total Operating Expenses	157	156	141	130	127	129	123	123	129	129	111
Selling, General & Admin Expense	57	62	57	51	46	44	40	40	50	54	48
Research & Development Expense	100	94	85	80	82	85	83	83	79	75	63
Total Other Income / (Expense), net	-19	-37	-37	-13	-17	-31	-7.16	-6.59	-13	-20	-34
Interest Expense	23	23	22	24	17	17	14	13	13	16	16
Other Income / (Expense), net	3.50	-15	-15	11	0.00	-14	6.84	6.78	0.00	-	-18
Other Gains / (Losses), net	14	-	17	-	7.91	-	-	-	6.43	-	-
Basic Earnings per Share	($1.36)	($1.26)	($1.36)	($1.31)	($1.33)	($1.38)	($1.35)	($1.34)	($1.38)	($1.53)	($1.52)
Weighted Average Basic Shares Outstanding	118.50M	111.98M	117.69M	109.24M	101.92M	96.52M	96.07M	95.76M	95.16M	89.83M	93.76M
Diluted Earnings per Share	($1.36)	($1.26)	($1.36)	($1.31)	($1.33)	($1.38)	($1.35)	($1.34)	($1.38)	($1.53)	($1.52)
Weighted Average Diluted Shares Outstanding	118.50M	111.98M	117.69M	109.24M	101.92M	96.52M	96.07M	95.76M	95.16M	89.83M	93.76M
Weighted Average Basic & Diluted Shares Outstanding	119.43M	118.41M	118.01M	117.66M	104.85M	103.00M	98.05M	96.00M	95.64M	95.16M	94.63M

This table details how cash moves in and out of Cytokinetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-18	46	-45	30	47	-5.82	-83	58	1.80	45
Net Cash From Operating Activities	-396	-414	-300	-143	8.94	-91	-101	-102	37	4.88
Net Cash From Continuing Operating Activities	-396	-414	-300	-143	8.94	-91	-101	-102	37	4.88
Net Income / (Loss) Continuing Operations	-590	-526	-389	-215	-127	-122	-106	-128	16	-38
Consolidated Net Income / (Loss)	-590	-526	-389	-215	-127	-122	-106	-128	16	-38
Depreciation Expense	9.53	12	5.81	2.28	1.83	1.29	1.24	1.92	0.74	0.59
Amortization Expense	-33	-16	-4.71	4.89	-1.19	-2.59	-1.68	0.00	-	-
Non-Cash Adjustments To Reconcile Net Income	174	111	115	57	51	41	35	24	7.66	4.55
Changes in Operating Assets and Liabilities, net	43	4.50	-26	8.46	85	-8.44	-30	0.49	12	37
Net Cash From Investing Activities	-553	239	-262	-148	-197	-75	5.13	-66	-52	16
Net Cash From Continuing Investing Activities	-553	239	-262	-148	-197	-75	5.13	-66	-52	16
Purchase of Property, Plant & Equipment	-3.91	-1.42	-11	-49	-11	-2.62	-0.89	-2.88	-1.60	-0.56
Purchase of Investments	-1,293	-635	-855	-525	-436	-278	-240	-240	-145	-116
Sale and/or Maturity of Investments	744	876	605	426	250	206	246	177	95	132
Net Cash From Financing Activities	931	221	516	320	234	160	13	226	17	24
Net Cash From Continuing Financing Activities	931	221	516	320	234	160	13	226	17	24
Repayment of Debt	-9.62	-0.86	-191	0.00	0.00	134	0.00	-	-	-
Issuance of Debt	200	50	673	0.00	0.00	1.71	9.90	16	17	15
Issuance of Common Equity	760	183	18	324	234	38	3.23	120	0.00	8.67
Other Financing Activities, net	-20	-11	17	-4.45	-0.10	-13	0.00	91	0.00	0.00
Other Net Changes in Cash	0.21	-0.02	0.00	-	-	-	-	-	-	-
Cash Interest Paid	26	10	15	9.18	9.62	4.06	2.88	2.13	1.90	0.09

This table details how cash moves in and out of Cytokinetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-21	48	-143	70	6.95	13	31	-34	36	-39	13
Net Cash From Operating Activities	-132	-66	-102	-99	-130	-74	-96	-122	-122	-98	-84
Net Cash From Continuing Operating Activities	-132	-66	-102	-99	-130	-74	-96	-122	-122	-98	-84
Net Income / (Loss) Continuing Operations	-161	-150	-161	-143	-136	-137	-129	-129	-131	-137	-142
Consolidated Net Income / (Loss)	-161	-150	-161	-143	-136	-137	-129	-129	-131	-137	-142
Depreciation Expense	2.30	2.38	2.41	2.41	2.33	6.34	1.85	1.86	1.85	1.66	1.41
Amortization Expense	-6.17	-7.70	-11	-8.50	-5.22	-5.10	-3.74	-3.86	-3.04	-4.22	-2.04
Non-Cash Adjustments To Reconcile Net Income	37	41	61	37	35	15	34	33	29	26	48
Changes in Operating Assets and Liabilities, net	-3.06	49	6.48	13	-26	46	1.29	-24	-19	16	11
Net Cash From Investing Activities	106	111	-45	-652	33	-81	73	82	165	29	-292
Net Cash From Continuing Investing Activities	106	111	-45	-652	33	-81	73	82	165	29	-292
Purchase of Property, Plant & Equipment	-5.66	-1.29	-0.70	-1.92	0.00	-0.08	-0.22	-0.72	-0.40	-3.21	-6.33
Purchase of Investments	-164	-121	-214	-815	-143	-226	-118	-202	-90	-125	-467
Sale and/or Maturity of Investments	276	233	170	166	175	145	191	284	256	158	181
Net Cash From Financing Activities	4.75	2.38	3.43	821	104	169	54	5.48	-7.18	30	389
Net Cash From Continuing Financing Activities	4.75	2.38	3.43	821	104	169	54	5.48	-7.18	30	389
Repayment of Debt	-2.88	-2.91	-2.89	-2.88	-0.93	-0.22	-0.22	-0.21	-0.21	-0.11	-141
Issuance of Common Equity	7.65	6.48	6.32	624	123	169	4.44	5.69	3.55	3.60	6.19
Other Financing Activities, net	-0.01	-1.18	-	-	-18	-	-	-	-11	26	-
Other Net Changes in Cash	-0.27	0.29	-0.13	-	-	-0.02	-	-	0.00	-	-
Cash Interest Paid	9.65	0.64	14	0.67	10	0.32	0.03	9.91	0.04	9.61	0.08

This table presents Cytokinetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	1,402	824	1,015	841	534	290	211	295	170	115
Total Current Assets	1,108	628	795	536	474	234	208	274	159	113
Cash & Equivalents	95	113	66	113	83	36	42	125	67	65
Short-Term Investments	981	502	717	359	381	189	156	144	89	46
Accounts Receivable	17	1.28	0.15	52	4.42	5.16	2.23	1.11	0.02	0.01
Prepaid Expenses	15	12	12	12	5.74	3.48	2.16	4.29	2.36	1.65
Plant, Property, & Equipment, net	66	69	80	73	13	4.53	3.20	3.57	3.64	1.75
Total Noncurrent Assets	228	128	139	232	46	52	0.30	17	7.87	0.38
Long-Term Investments	145	41	47	152	37	43	0.00	17	7.67	0.18
Other Noncurrent Operating Assets	83	87	92	80	9.28	8.88	0.30	0.43	0.20	0.20
Total Liabilities & Shareholders' Equity	1,402	824	1,015	841	534	290	211	295	170	115
Total Liabilities	1,537	1,211	1,123	597	420	301	185	185	76	47
Total Current Liabilities	180	103	85	72	31	26	22	32	33	32
Short-Term Debt	12	10	0.96	-	2.79	-	2.61	0.00	2.50	0.00
Accounts Payable	20	22	26	21	8.05	8.16	3.76	5.25	4.24	2.24
Accrued Expenses	55	43	44	34	19	12	16	17	18	8.42
Current Deferred Revenue	52	0.00	-	-	-	-	-	9.57	8.06	21
Other Current Liabilities	40	28	14	16	1.05	5.74	0.07	0.23	0.42	0.13
Total Noncurrent Liabilities	1,357	1,108	1,038	526	389	275	163	153	43	15
Long-Term Debt	646	607	610	143	136	129	40	32	27	15
Other Noncurrent Operating Liabilities	712	501	428	296	166	145	123	106	0.14	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-135	-386	-108	244	113	-11	26	110	94	69
Total Preferred & Common Equity	-135	-386	-108	244	113	-11	26	110	94	69
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-135	-386	-108	244	113	-11	26	110	94	69
Common Stock	2,564	1,726	1,482	1,452	1,106	853	769	756	613	603
Retained Earnings	-2,702	-2,112	-1,586	-1,208	-992	-865	-743	-646	-518	-535
Accumulated Other Comprehensive Income / (Loss)	2.40	-0.01	-3.59	-0.87	0.15	0.68	0.50	0.34	0.14	0.15

This table presents Cytokinetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,264	1,436	1,524	808	741	780	890	1,076
Total Current Assets	956	1,019	1,068	639	561	587	681	884
Cash & Equivalents	74	47	190	120	100	69	102	106
Short-Term Investments	865	965	867	499	440	497	562	761
Accounts Receivable	2.01	0.24	0.00	0.83	2.50	0.99	1.01	2.29
Prepaid Expenses	16	6.67	11	19	20	20	16	14
Plant, Property, & Equipment, net	67	64	66	68	76	77	79	80
Total Noncurrent Assets	241	353	390	101	104	116	130	111
Long-Term Investments	151	269	305	15	15	27	40	29
Other Noncurrent Operating Assets	90	84	85	86	88	89	90	83
Total Liabilities & Shareholders' Equity	1,264	1,436	1,524	808	741	780	890	1,076
Total Liabilities	1,530	1,450	1,415	1,204	1,179	1,113	1,119	1,092
Total Current Liabilities	160	110	103	89	78	66	75	76
Short-Term Debt	13	12	12	12	-	-	-	-
Accounts Payable	14	12	9.47	13	14	13	17	14
Accrued Expenses	43	50	40	40	33	31	36	40
Current Deferred Revenue	52	-	-	-	-	-	-	-
Other Current Liabilities	37	37	42	24	31	22	22	22
Total Noncurrent Liabilities	1,371	1,340	1,312	1,115	1,102	1,047	1,044	1,015
Long-Term Debt	645	644	643	607	609	610	611	609
Other Noncurrent Operating Liabilities	726	696	669	509	493	438	433	407
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	-266	-14	109	-396	-439	-333	-229	-16
Total Preferred & Common Equity	-266	-14	109	-396	-439	-333	-229	-16
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-266	-14	109	-396	-439	-333	-229	-16
Common Stock	2,595	2,532	2,501	1,852	1,537	1,514	1,490	1,438
Retained Earnings	-2,863	-2,552	-2,391	-2,248	-1,975	-1,846	-1,717	-1,449
Accumulated Other Comprehensive Income / (Loss)	1.55	5.39	-1.02	-0.54	-0.87	-1.46	-1.65	-5.56

This table displays calculated financial ratios and metrics derived from Cytokinetics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	145.34%	-92.04%	34.30%	26.15%	107.79%	-14.71%	135.64%	-87.44%	271.30%	-38.95%
EBITDA Growth	-15.50%	-43.68%	-94.28%	-92.00%	2.43%	-12.49%	21.92%	-647.33%	154.28%	-158.86%
EBIT Growth	-11.76%	-42.12%	-87.39%	-98.33%	0.41%	-11.55%	23.67%	-678.53%	151.44%	-154.22%
NOPAT Growth	-8.07%	-53.05%	-74.01%	-98.33%	4.98%	-11.19%	21.59%	-524.77%	171.37%	-153.54%
Net Income Growth	-12.03%	-35.30%	-80.65%	-69.15%	-4.60%	-14.49%	16.83%	-876.70%	143.87%	-156.05%
EPS Growth	3.49%	-25.87%	-54.64%	-42.13%	6.64%	-8.21%	24.71%	-764.10%	140.21%	-136.59%
Operating Cash Flow Growth	4.45%	-38.33%	-110.15%	-1,693.67%	109.84%	10.18%	0.53%	-375.16%	657.36%	110.89%
Free Cash Flow Firm Growth	59.84%	-81.86%	3.38%	-524.37%	166.78%	33.71%	-405.85%	-17.48%	171.43%	124.57%
Invested Capital Growth	-64.85%	-29.89%	-37.82%	4.71%	-66.41%	-14.62%	9.32%	-262.38%	-39.75%	-421.32%
Revenue Q/Q Growth	473.90%	-3.65%	-36.19%	226.81%	2.78%	-13.42%	42.50%	-71.27%	28.16%	-29.52%
EBITDA Q/Q Growth	-3.46%	0.68%	-63.38%	8.77%	-22.15%	-1.95%	17.51%	-60.94%	565.95%	-90.32%
EBIT Q/Q Growth	-2.35%	-0.08%	-59.52%	7.31%	-22.43%	-2.14%	18.67%	-60.15%	725.83%	-87.77%
NOPAT Q/Q Growth	-2.22%	-0.08%	-48.12%	7.31%	-15.63%	-2.33%	14.49%	-63.91%	844.26%	-87.36%
Net Income Q/Q Growth	-2.28%	0.09%	-37.86%	5.84%	-11.66%	-3.55%	11.65%	-59.44%	24,456.72%	-89.12%
EPS Q/Q Growth	2.23%	2.68%	-38.34%	8.20%	-3.68%	-1.44%	12.95%	-61.88%	657.14%	-90.20%
Operating Cash Flow Q/Q Growth	2.09%	5.51%	-21.72%	-212.31%	114.36%	-7.99%	10.40%	-72,269.50%	172.82%	-27.07%
Free Cash Flow Firm Q/Q Growth	11.24%	6.20%	-6.86%	-384.11%	210.09%	-17.11%	13.31%	-77.62%	152.75%	40.85%
Invested Capital Q/Q Growth	-9.48%	-10.34%	-7.56%	15.04%	-48.39%	-5.88%	-12.08%	-9.92%	-241.10%	7.47%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-3,126.19%	-6,640.74%	-367.95%	-254.36%	-167.13%	-355.91%	-269.85%	-814.44%	18.69%	-127.87%
Operating Margin	-2,902.72%	-6,589.71%	-342.75%	-264.54%	-168.27%	-367.97%	-282.26%	-848.26%	17.56%	-130.53%
EBIT Margin	-3,001.78%	-6,589.71%	-369.12%	-264.54%	-168.27%	-351.09%	-268.46%	-828.80%	18.00%	-129.92%
Profit (Net Income) Margin	-3,191.11%	-6,988.63%	-411.21%	-305.72%	-228.00%	-452.93%	-337.41%	-955.94%	15.46%	-130.86%
Tax Burden Percent	91.96%	95.01%	97.17%	99.85%	95.98%	100.00%	100.15%	100.00%	100.00%	100.00%
Interest Burden Percent	115.60%	111.62%	114.65%	115.74%	141.17%	129.00%	125.50%	115.34%	85.91%	100.72%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	226.00%	212.96%	-572.15%	-120.54%	-248.50%	-1,622.88%	-156.57%	-125.16%	20.19%	-46.69%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-49.82%	-53.96%	-37.62%	-27.10%	-22.81%	-37.66%	-33.43%	-47.66%	13.42%	-30.00%
Return on Assets (ROA)	-52.97%	-57.23%	-41.91%	-31.32%	-30.91%	-48.58%	-42.01%	-54.97%	11.53%	-30.22%
Return on Common Equity (ROCE)	226.00%	212.96%	-572.15%	-120.54%	-248.50%	-1,622.88%	-156.57%	-125.16%	20.19%	-46.69%
Return on Equity Simple (ROE_SIMPLE)	435.49%	136.22%	360.48%	-88.29%	-112.27%	1,112.66%	-409.84%	-116.34%	17.44%	-54.67%
Net Operating Profit after Tax (NOPAT)	-375	-347	-227	-130	-66	-69	-62	-79	19	-26
NOPAT Margin	-2,031.90%	-4,612.80%	-239.93%	-185.18%	-117.79%	-257.58%	-197.58%	-593.79%	17.56%	-91.37%
Net Nonoperating Expense Percent (NNEP)	-71.16%	-139.43%	-46.32%	-20.14%	-24.58%	-35.60%	-21.49%	-24.98%	-1.93%	-12.56%
Return On Investment Capital (ROIC_SIMPLE)	-71.95%	-150.28%	-45.15%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	1,165.50%	2,305.60%	188.16%	137.45%	94.61%	147.42%	99.30%	272.80%	26.15%	68.63%
R&D to Revenue	1,837.22%	4,384.10%	254.59%	227.09%	173.66%	320.55%	282.96%	675.46%	56.29%	161.90%
Operating Expenses to Revenue	3,002.72%	6,689.71%	442.75%	364.54%	268.27%	467.97%	382.26%	948.26%	82.44%	230.53%
Earnings before Interest and Taxes (EBIT)	-555	-496	-349	-186	-94	-94	-85	-111	19	-37
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-578	-500	-348	-179	-93	-96	-85	-109	20	-37
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	15.68	12.97	0.00	13.33	4.00	5.22	5.92
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	15.68	12.97	0.00	13.33	4.00	5.22	5.92
Price to Revenue (P/Rev)	300.50	1,087.18	45.84	54.29	26.35	23.33	10.98	32.85	4.63	14.18
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	29.92	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3.34%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	269.97	1,082.15	43.53	47.46	19.86	18.18	6.01	13.88	3.37	10.79
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.01	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	18.71	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	19.17	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	123.98	0.00	0.00	0.00	9.69	63.35
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	33.10	0.00	0.00	7.50	11.95	28.01
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-4.85	-1.60	-5.66	0.59	1.23	-11.82	1.64	0.29	0.32	0.21
Long-Term Debt to Equity	-4.77	-1.57	-5.65	0.59	1.20	-11.82	1.53	0.29	0.29	0.21
Financial Leverage	1.15	0.52	-5.15	-2.36	-4.89	-19.66	-3.02	-1.90	-1.42	-1.12
Leverage Ratio	-4.27	-3.72	13.65	3.85	8.04	33.41	3.73	2.28	1.75	1.55
Compound Leverage Factor	-4.93	-4.15	15.65	4.46	11.35	43.10	4.68	2.63	1.50	1.56
Debt to Total Capital	125.95%	267.15%	121.47%	36.94%	55.06%	109.24%	62.06%	22.44%	24.05%	17.59%
Short-Term Debt to Total Capital	2.21%	4.36%	0.19%	0.00%	1.10%	0.00%	3.81%	0.00%	2.01%	0.00%
Long-Term Debt to Total Capital	123.74%	262.78%	121.27%	36.94%	53.96%	109.24%	58.24%	22.44%	22.04%	17.59%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-25.95%	-167.15%	-21.47%	63.06%	44.94%	-9.24%	37.94%	77.56%	75.95%	82.41%
Debt to EBITDA	-1.14	-1.23	-1.75	-0.80	-1.49	-1.35	-0.50	-0.29	1.50	-0.40
Net Debt to EBITDA	0.98	0.08	0.63	2.68	3.88	1.45	1.84	2.33	-6.74	2.65
Long-Term Debt to EBITDA	-1.12	-1.21	-1.75	-0.80	-1.46	-1.35	-0.47	-0.29	1.38	-0.40
Debt to NOPAT	-1.75	-1.78	-2.69	-1.10	-2.11	-1.87	-0.68	-0.40	1.60	-0.56
Net Debt to NOPAT	1.50	0.11	0.96	3.69	5.51	2.00	2.51	3.20	-7.17	3.70
Long-Term Debt to NOPAT	-1.72	-1.75	-2.69	-1.10	-2.07	-1.87	-0.64	-0.40	1.47	-0.56
Altman Z-Score	-1.03	-0.74	-0.07	1.84	0.02	-3.05	-3.93	-1.85	1.51	-1.24
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.17	6.12	9.40	7.45	15.20	8.98	9.36	8.45	4.77	3.57
Quick Ratio	6.08	6.00	9.25	7.28	15.02	8.85	9.05	8.32	4.70	3.52
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-100	-250	-137	-142	33	-50	-76	25	30	11
Operating Cash Flow to CapEx	-10,135.43%	-29,260.81%	-2,642.40%	-291.62%	80.92%	-3,471.06%	-11,567.43%	-3,536.98%	2,366.09%	870.41%
Free Cash Flow to Firm to Interest Expense	-1.16	-4.33	-2.68	-4.85	0.87	-1.83	-3.51	1.46	11.11	41.21
Operating Cash Flow to Interest Expense	-4.58	-7.18	-5.86	-4.86	0.23	-3.32	-4.69	-5.99	13.71	18.22
Operating Cash Flow Less CapEx to Interest Expense	-4.62	-7.21	-6.08	-6.53	-0.05	-3.42	-4.73	-6.16	13.13	16.13
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.01	0.10	0.10	0.14	0.11	0.12	0.06	0.75	0.23
Accounts Receivable Turnover	2.06	10.53	3.64	2.50	11.65	7.27	18.85	23.54	5,911.50	1.23
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.27	0.10	1.23	1.63	6.25	6.95	9.30	3.71	39.50	16.92
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	177.16	34.66	100.26	145.73	31.33	50.22	19.37	15.51	0.06	297.13
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	177.16	34.66	100.26	145.73	31.33	50.22	19.37	15.51	0.06	297.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-699	-424	-327	-237	-249	-149	-130	-144	-40	-28
Invested Capital Turnover	-0.03	-0.02	-0.34	-0.29	-0.28	-0.19	-0.23	-0.15	-3.13	-2.93
Increase / (Decrease) in Invested Capital	-275	-98	-90	12	-99	-19	13	-104	-11	-37
Enterprise Value (EV)	4,987	8,149	4,117	3,343	1,109	488	189	186	358	309
Market Capitalization	5,551	8,186	4,336	3,823	1,471	627	346	439	492	406
Book Value per Share	($1.15)	($3.94)	($1.14)	$2.91	$1.60	($0.19)	$0.47	$2.04	$2.33	$1.77
Tangible Book Value per Share	($1.15)	($3.94)	($1.14)	$2.91	$1.60	($0.19)	$0.47	$2.04	$2.33	$1.77
Total Capital	522	231	503	387	252	118	68	142	124	83
Total Debt	657	617	611	143	139	129	42	32	30	15
Total Long-Term Debt	646	607	610	143	136	129	40	32	27	15
Net Debt	-564	-38	-219	-481	-362	-139	-156	-254	-134	-97
Capital Expenditures (CapEx)	3.91	1.42	11	49	11	2.62	0.88	2.88	1.56	0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-136	-79	-71	-7.83	-18	-17	-11	-27	-28	-30
Debt-free Net Working Capital (DFNWC)	940	535	712	464	446	208	188	242	128	81
Net Working Capital (NWC)	928	525	711	464	443	208	185	242	125	81
Net Nonoperating Expense (NNE)	214	179	162	85	62	52	44	48	2.23	11
Net Nonoperating Obligations (NNO)	-564	-38	-219	-481	-362	-139	-156	-254	-134	-97
Total Depreciation and Amortization (D&A)	-23	-3.84	1.10	7.17	0.64	-1.29	-0.44	1.92	0.74	0.59
Debt-free, Cash-free Net Working Capital to Revenue	-737.40%	-1,054.06%	-75.12%	-11.11%	-32.70%	-64.70%	-33.79%	-202.27%	-26.67%	-104.63%
Debt-free Net Working Capital to Revenue	5,087.07%	7,110.93%	752.24%	658.56%	798.54%	773.15%	597.08%	1,809.18%	120.18%	284.24%
Net Working Capital to Revenue	5,024.72%	6,977.07%	751.23%	658.56%	793.55%	773.15%	588.81%	1,809.18%	117.83%	284.24%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.26)	($5.45)	($4.33)	($2.80)	($1.97)	($2.11)	($1.95)	($2.59)	$0.41	($0.97)
Adjusted Weighted Average Basic Shares Outstanding	111.98M	96.52M	89.83M	84.86M	71.11M	59.45M	54.89M	49.40M	39.94M	39.59M
Adjusted Diluted Earnings per Share	($5.26)	($5.45)	($4.33)	($2.80)	($1.97)	($2.11)	($1.95)	($2.59)	$0.39	($0.97)
Adjusted Weighted Average Diluted Shares Outstanding	111.98M	96.52M	89.83M	84.86M	71.11M	59.45M	54.89M	49.40M	42.56M	39.59M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($2.80)	($1.97)	($2.11)	($1.95)	$0.00	$0.00	($0.97)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	118.41M	103.00M	95.16M	76.89M	64.52M	57.58M	54.42M	54.01M	41.73M	38.81M
Normalized Net Operating Profit after Tax (NOPAT)	-375	-347	-227	-130	-66	-69	-62	-79	13	-26
Normalized NOPAT Margin	-2,031.90%	-4,612.80%	-239.93%	-185.18%	-117.79%	-257.58%	-197.58%	-593.79%	12.29%	-91.37%
Pre Tax Income Margin	-3,470.07%	-7,355.55%	-423.20%	-306.19%	-237.55%	-452.93%	-336.92%	-955.94%	15.46%	-130.86%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-6.41	-8.60	-6.83	-6.35	-2.43	-3.45	-3.92	-6.52	7.10	-138.93
NOPAT to Interest Expense	-4.34	-6.02	-4.44	-4.45	-1.70	-2.53	-2.89	-4.67	6.93	-97.70
EBIT Less CapEx to Interest Expense	-6.46	-8.63	-7.05	-8.02	-2.71	-3.54	-3.96	-6.69	6.52	-141.02
NOPAT Less CapEx to Interest Expense	-4.38	-6.05	-4.66	-6.11	-1.99	-2.63	-2.93	-4.84	6.35	-99.80
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Cytokinetics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	89.10%	912.38%	22.49%	-71.28%	-81.90%	-14.56%	-84.97%	-99.03%	301.83%	-96.48%	-53.74%
EBITDA Growth	-20.81%	-13.81%	-39.79%	-6.85%	-2.76%	-7.88%	7.76%	-1,214.02%	-60.68%	-564.02%	-88.92%
EBIT Growth	-20.51%	-9.05%	-34.55%	-3.43%	-1.42%	-11.03%	8.79%	-960.05%	-54.53%	-485.28%	-82.86%
NOPAT Growth	-23.29%	-9.12%	-15.16%	-6.66%	-1.42%	-0.31%	-12.75%	-1,022.39%	-59.87%	-485.28%	-56.70%
Net Income Growth	-18.97%	-9.59%	-24.05%	-11.41%	-3.32%	0.35%	9.06%	-549.03%	-46.78%	-349.39%	-87.04%
EPS Growth	-2.26%	8.70%	-0.74%	2.24%	3.62%	9.80%	11.18%	-482.61%	-31.43%	-363.64%	-60.00%
Operating Cash Flow Growth	-1.63%	11.44%	-5.50%	18.47%	-5.91%	24.60%	-14.48%	-34.63%	-356.10%	-119.48%	-116.77%
Free Cash Flow Firm Growth	14,135.80%	2,009.66%	3,376.93%	431.65%	100.89%	1,102.05%	90.72%	-569.58%	-192.17%	102.61%	-181.39%
Invested Capital Growth	-69.07%	-64.85%	-66.13%	-89.48%	-27.76%	-29.89%	-26.62%	-9.60%	13.73%	-37.82%	-8.86%
Revenue Q/Q Growth	-90.67%	3,555.94%	85.94%	-70.18%	-50.06%	342.33%	-56.40%	-81.21%	135.72%	-22.19%	-97.17%
EBITDA Q/Q Growth	1.95%	2.97%	-30.86%	2.96%	7.64%	-19.18%	-0.03%	6.67%	3.03%	-1.90%	-1,324.91%
EBIT Q/Q Growth	1.08%	0.97%	-30.27%	5.56%	10.49%	-22.19%	-0.14%	7.39%	2.01%	-0.38%	-1,063.72%
NOPAT Q/Q Growth	-11.93%	1.25%	-8.17%	-3.12%	0.93%	-4.21%	-0.18%	1.95%	2.01%	-17.14%	-897.25%
Net Income Q/Q Growth	-7.57%	6.56%	-12.02%	-5.66%	0.92%	-5.77%	-0.61%	2.02%	4.43%	3.46%	-618.01%
EPS Q/Q Growth	-7.94%	7.35%	-3.82%	1.50%	3.62%	-2.22%	-0.75%	2.90%	9.80%	-0.66%	-560.87%
Operating Cash Flow Q/Q Growth	-100.73%	35.40%	-2.20%	23.31%	-74.92%	23.04%	21.02%	0.39%	-24.54%	-16.84%	7.11%
Free Cash Flow Firm Q/Q Growth	-1.06%	14.17%	-18.73%	15,406.81%	-85.34%	277.34%	91.77%	58.29%	-19,855.51%	101.37%	-516.20%
Invested Capital Q/Q Growth	0.31%	-9.48%	-6.70%	-45.17%	2.80%	-10.34%	-21.70%	2.12%	1.18%	-7.56%	-5.34%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
EBITDA Margin	-9,879.99%	-939.98%	-35,417.06%	-50,326.10%	-15,464.43%	-8,361.36%	-31,033.86%	-13,526.64%	-2,724.08%	-6,621.87%	-5,056.58%
Operating Margin	-9,856.30%	-821.41%	-30,410.58%	-52,277.91%	-15,117.96%	-7,620.69%	-32,345.24%	-14,077.16%	-2,698.31%	-6,491.06%	-4,311.77%
EBIT Margin	-9,634.64%	-908.57%	-33,542.33%	-47,879.12%	-15,117.96%	-8,435.17%	-30,535.98%	-13,295.27%	-2,698.31%	-6,491.06%	-5,031.53%
Profit (Net Income) Margin	-10,220.14%	-886.28%	-34,674.95%	-57,557.43%	-16,244.67%	-8,187.56%	-34,238.62%	-14,837.02%	-2,846.07%	-7,019.93%	-5,658.45%
Tax Burden Percent	92.17%	85.05%	90.40%	99.86%	94.49%	86.59%	100.00%	100.00%	95.33%	93.18%	100.00%
Interest Burden Percent	115.08%	114.69%	114.36%	120.38%	113.72%	112.10%	112.13%	111.60%	110.64%	116.07%	112.46%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	185.72%	226.00%	254.64%	485.63%	169.74%	212.96%	231.64%	486.80%	764.11%	-572.15%	-242.14%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-178.71%	-15.08%	-99.21%	-130.27%	-66.82%	-69.07%	-262.73%	-170.55%	-303.06%	-661.58%	-783.64%
Return on Assets (ROA)	-189.57%	-14.71%	-102.56%	-156.61%	-71.79%	-67.05%	-294.59%	-190.33%	-319.65%	-715.48%	-881.28%
Return on Common Equity (ROCE)	185.72%	226.00%	254.64%	485.63%	169.74%	212.96%	231.64%	486.80%	764.11%	-572.15%	-242.14%
Return on Equity Simple (ROE_SIMPLE)	230.94%	0.00%	4,143.50%	-502.33%	133.94%	0.00%	120.04%	161.99%	188.11%	0.00%	1,765.94%
Net Operating Profit after Tax (NOPAT)	-109	-97	-99	-91	-88	-89	-86	-85	-87	-89	-76
NOPAT Margin	-6,899.41%	-574.99%	-21,287.41%	-36,594.54%	-10,582.57%	-5,334.49%	-22,641.67%	-9,854.01%	-1,888.82%	-4,543.74%	-3,018.24%
Net Nonoperating Expense Percent (NNEP)	-23.46%	-17.51%	-21.73%	-15.13%	-86.00%	-37.18%	-37.57%	-22.59%	-15.12%	-13.85%	-16.28%
Return On Investment Capital (ROIC_SIMPLE)	-27.81%	-18.65%	-	-	-	-38.59%	-	-	-	-17.69%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	3,633.25%	368.28%	12,235.85%	20,411.25%	5,449.10%	2,638.40%	10,611.38%	4,581.55%	1,076.63%	2,757.74%	1,917.38%
R&D to Revenue	6,323.05%	553.13%	18,274.73%	31,966.67%	9,768.86%	5,082.30%	21,833.86%	9,595.62%	1,721.68%	3,833.32%	2,494.39%
Operating Expenses to Revenue	9,956.30%	921.41%	30,510.58%	52,377.91%	15,217.96%	7,720.69%	32,445.24%	14,177.16%	2,798.31%	6,591.06%	4,411.77%
Earnings before Interest and Taxes (EBIT)	-152	-154	-155	-119	-126	-141	-115	-115	-124	-127	-127
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-156	-159	-164	-125	-129	-140	-117	-117	-126	-130	-127
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.00	52.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	52.34	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	247.63	300.50	1,929.92	1,812.69	1,832.23	1,087.18	361.88	313.48	34.15	45.84	30.77
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	225.21	269.97	1,735.81	1,587.05	1,827.91	1,082.15	368.83	315.21	33.20	43.53	28.83
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	-2.47	-4.85	-47.16	6.03	-1.56	-1.60	-1.39	-1.83	-2.67	-5.66	-38.09
Long-Term Debt to Equity	-2.42	-4.77	-46.33	5.93	-1.53	-1.57	-1.39	-1.83	-2.67	-5.65	-38.09
Financial Leverage	0.67	1.15	1.26	3.07	0.18	0.52	0.51	1.73	5.18	-5.15	-3.50
Leverage Ratio	-3.13	-4.27	-4.81	-10.26	-2.72	-3.72	-3.99	-7.00	-15.49	13.65	8.17
Compound Leverage Factor	-3.60	-4.89	-5.50	-12.35	-3.09	-4.17	-4.48	-7.81	-17.13	15.85	9.19
Debt to Total Capital	168.01%	125.95%	102.17%	85.78%	278.47%	267.15%	357.79%	220.40%	160.02%	121.47%	102.70%
Short-Term Debt to Total Capital	3.31%	2.21%	1.79%	1.51%	5.19%	4.36%	0.00%	0.00%	0.00%	0.19%	0.00%
Long-Term Debt to Total Capital	164.70%	123.74%	100.37%	84.27%	273.28%	262.78%	357.79%	220.40%	160.02%	121.27%	102.70%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	-68.01%	-25.95%	-2.17%	14.22%	-178.47%	-167.15%	-257.79%	-120.40%	-60.02%	-21.47%	-2.70%
Debt to EBITDA	-1.09	-1.14	-1.18	-1.28	-1.23	-1.23	-1.21	-1.25	-1.54	-1.75	-2.86
Net Debt to EBITDA	0.71	0.98	1.12	1.38	0.03	0.08	-0.11	-0.04	0.24	0.63	1.35
Long-Term Debt to EBITDA	-1.07	-1.12	-1.15	-1.26	-1.20	-1.21	-1.21	-1.25	-1.54	-1.75	-2.86
Debt to NOPAT	-1.66	-1.75	-1.79	-1.85	-1.77	-1.78	-1.75	-1.81	-2.35	-2.69	-3.97
Net Debt to NOPAT	1.09	1.50	1.70	2.00	0.05	0.11	-0.16	-0.05	0.36	0.96	1.88
Long-Term Debt to NOPAT	-1.63	-1.72	-1.76	-1.82	-1.74	-1.75	-1.75	-1.81	-2.35	-2.69	-3.97
Altman Z-Score	-0.93	-0.09	0.49	0.72	-0.16	0.68	-2.02	-1.31	-0.44	0.65	1.27
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.99	6.17	9.28	10.39	7.19	6.12	7.22	8.94	9.05	9.40	11.56
Quick Ratio	5.89	6.08	9.22	10.28	6.98	6.00	6.97	8.64	8.84	9.25	11.37
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	176	178	156	192	1.24	8.43	-4.75	-58	-138	0.70	-51
Operating Cash Flow to CapEx	-2,323.75%	-5,082.95%	-14,479.32%	-5,186.06%	0.00%	-96,151.95%	-43,729.55%	-16,988.15%	-30,419.40%	-3,063.65%	-1,327.44%
Free Cash Flow to Firm to Interest Expense	7.67	7.87	6.98	7.88	0.07	0.49	-0.34	-4.32	-10.46	0.04	-3.25
Operating Cash Flow to Interest Expense	-5.74	-2.90	-4.55	-4.09	-7.48	-4.34	-6.87	-9.11	-9.24	-6.04	-5.33
Operating Cash Flow Less CapEx to Interest Expense	-5.98	-2.96	-4.58	-4.17	-7.48	-4.34	-6.89	-9.17	-9.27	-6.23	-5.73
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.02	0.02	0.00	0.00	0.00	0.01	0.01	0.01	0.11	0.10	0.16
Accounts Receivable Turnover	13.51	2.06	2.35	0.00	4.08	10.53	3.26	6.73	27.77	3.64	100.91
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.28	0.27	0.05	0.04	0.05	0.10	0.10	0.13	1.27	1.23	2.21
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	27.03	177.16	155.51	0.00	89.50	34.66	111.93	54.24	13.14	100.26	3.62
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	27.03	177.16	155.51	0.00	89.50	34.66	111.93	54.24	13.14	100.26	3.62
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-697	-699	-639	-599	-412	-424	-384	-316	-323	-327	-304
Invested Capital Turnover	-0.03	-0.03	-0.01	-0.01	-0.01	-0.02	-0.02	-0.03	-0.28	-0.34	-0.51
Increase / (Decrease) in Invested Capital	-285	-275	-254	-283	-90	-98	-81	-28	51	-90	-25
Enterprise Value (EV)	4,328	4,987	5,588	4,974	6,858	8,149	2,882	3,137	3,255	4,117	4,274
Market Capitalization	4,759	5,551	6,212	5,681	6,875	8,186	2,828	3,120	3,349	4,336	4,561
Book Value per Share	($2.25)	($1.15)	($0.12)	$1.04	($3.89)	($3.94)	($4.57)	($3.48)	($2.41)	($1.14)	($0.17)
Tangible Book Value per Share	($2.25)	($1.15)	($0.12)	$1.04	($3.89)	($3.94)	($4.57)	($3.48)	($2.41)	($1.14)	($0.17)
Total Capital	392	522	642	764	222	231	170	277	382	503	593
Total Debt	658	657	656	655	618	617	609	610	611	611	609
Total Long-Term Debt	645	646	644	643	607	607	609	610	611	610	609
Net Debt	-431	-564	-625	-707	-16	-38	54	17	-94	-219	-288
Capital Expenditures (CapEx)	5.66	1.29	0.70	1.92	0.00	0.08	0.22	0.72	0.40	3.21	6.33
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-129	-136	-91	-80	-58	-79	-56	-45	-59	-71	-60
Debt-free Net Working Capital (DFNWC)	809	940	920	977	561	535	484	521	605	712	808
Net Working Capital (NWC)	796	928	909	965	550	525	484	521	605	711	808
Net Nonoperating Expense (NNE)	52	53	62	52	47	48	44	43	44	48	66
Net Nonoperating Obligations (NNO)	-431	-564	-625	-707	-16	-38	54	17	-94	-219	-288
Total Depreciation and Amortization (D&A)	-3.87	-5.32	-8.68	-6.09	-2.89	1.23	-1.88	-2.01	-1.19	-2.56	-0.63
Debt-free, Cash-free Net Working Capital to Revenue	-670.89%	-737.40%	-2,838.86%	-2,559.73%	-1,534.97%	-1,054.06%	-710.76%	-449.80%	-59.72%	-75.12%	-40.40%
Debt-free Net Working Capital to Revenue	4,211.09%	5,087.07%	28,589.90%	31,159.96%	14,961.86%	7,110.93%	6,189.29%	5,234.71%	617.43%	752.24%	544.95%
Net Working Capital to Revenue	4,143.65%	5,024.72%	28,232.03%	30,792.37%	14,654.82%	6,977.07%	6,189.29%	5,234.71%	617.43%	751.23%	544.95%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.36)	($1.26)	($1.36)	($1.31)	($1.33)	($1.38)	($1.35)	($1.34)	($1.38)	($1.53)	($1.52)
Adjusted Weighted Average Basic Shares Outstanding	118.50M	111.98M	117.69M	109.24M	101.92M	96.52M	96.07M	95.76M	95.16M	89.83M	93.76M
Adjusted Diluted Earnings per Share	($1.36)	($1.26)	($1.36)	($1.31)	($1.33)	($1.38)	($1.35)	($1.34)	($1.38)	($1.53)	($1.52)
Adjusted Weighted Average Diluted Shares Outstanding	118.50M	111.98M	117.69M	109.24M	101.92M	96.52M	96.07M	95.76M	95.16M	89.83M	93.76M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	119.43M	118.41M	118.01M	117.66M	104.85M	103.00M	98.05M	96.00M	95.64M	95.16M	94.63M
Normalized Net Operating Profit after Tax (NOPAT)	-109	-97	-99	-91	-88	-89	-86	-85	-87	-89	-76
Normalized NOPAT Margin	-6,899.41%	-574.99%	-21,287.41%	-36,594.54%	-10,582.57%	-5,334.49%	-22,641.67%	-9,854.01%	-1,888.82%	-4,543.74%	-3,018.24%
Pre Tax Income Margin	-11,087.84%	-1,042.05%	-38,358.32%	-57,637.75%	-17,192.34%	-9,455.74%	-34,238.62%	-14,837.02%	-2,985.35%	-7,534.13%	-5,658.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-6.63	-6.81	-6.96	-4.91	-7.29	-8.27	-8.25	-8.62	-9.40	-7.81	-8.03
NOPAT to Interest Expense	-4.75	-4.31	-4.42	-3.75	-5.10	-5.23	-6.12	-6.39	-6.58	-5.47	-4.81
EBIT Less CapEx to Interest Expense	-6.88	-6.86	-7.00	-4.99	-7.29	-8.27	-8.26	-8.68	-9.43	-8.01	-8.43
NOPAT Less CapEx to Interest Expense	-4.99	-4.36	-4.45	-3.83	-5.10	-5.23	-6.13	-6.45	-6.61	-5.66	-5.22
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Cytokinetics' Financials

When does Cytokinetics's financial year end?

According to the most recent income statement we have on file, Cytokinetics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Cytokinetics' net income changed over the last 9 years?

Cytokinetics' net income appears to be on an upward trend, with a most recent value of -$589.53 million in 2024, rising from -$37.50 million in 2015. The previous period was -$526.24 million in 2023. Find out what analysts predict for Cytokinetics in the coming months.

What is Cytokinetics's operating income?

Cytokinetics's total operating income in 2024 was -$536.25 million, based on the following breakdown:

Total Gross Profit: $18.47 million
Total Operating Expenses: $554.72 million

How has Cytokinetics revenue changed over the last 9 years?

Over the last 9 years, Cytokinetics' total revenue changed from $28.66 million in 2015 to $18.47 million in 2024, a change of -35.5%.

How much debt does Cytokinetics have?

Cytokinetics' total liabilities were at $1.54 billion at the end of 2024, a 27.0% increase from 2023, and a 3,195.1% increase since 2015.

How much cash does Cytokinetics have?

In the past 9 years, Cytokinetics' cash and equivalents has ranged from $36.43 million in 2019 to $125.21 million in 2017, and is currently $94.86 million as of their latest financial filing in 2024.

How has Cytokinetics' book value per share changed over the last 9 years?

Over the last 9 years, Cytokinetics' book value per share changed from 1.77 in 2015 to -1.15 in 2024, a change of -165.0%.

Related Companies

This page (NASDAQ:CYTK) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytokinetics (CYTK) Financials

Frequently Asked Questions About Cytokinetics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytokinetics (CYTK) Financials

Annual Income Statements for Cytokinetics

Quarterly Income Statements for Cytokinetics

Annual Cash Flow Statements for Cytokinetics

Quarterly Cash Flow Statements for Cytokinetics

Annual Balance Sheets for Cytokinetics

Quarterly Balance Sheets for Cytokinetics

Annual Metrics And Ratios for Cytokinetics

Quarterly Metrics And Ratios for Cytokinetics

Frequently Asked Questions About Cytokinetics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools